Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin.

Altersabhängige Hämato- und Nephrotoxizität bei Patienten mit Kopf-Hals-Tumoren unter Radiochemotherapie mit wöchentlicher Cisplatin-Gabe.

Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 06 05 2019
accepted: 06 11 2019
pubmed: 1 12 2019
medline: 15 12 2020
entrez: 1 12 2019
Statut: ppublish

Résumé

In cases of simultaneous chemoradiotherapy (CRT), early recognition of toxic side effects is important, as drug discontinuation may prevent further injury. It appears favorable to undertake further steps to investigate whether patient subgroups behave differently depending on their toxicity profile. We retrospectively analyzed 125 consecutive patients with non-metastasized carcinoma of the head and neck who were treated with CRT (cisplatin 40 mg/m Eighty-six patients did not reach the intended sixth cycle (68.8%; 60.0% of whom were ≥60 years, p < 0.05). Acute kidney injury (glomerular filtration rate <60 mL/min/1.73m Acute kidney injury was the most common side effect in patients ≥60 years, whereas leukopenia characteristically occurred significantly more often in younger patients. Discontinuing cisplatin during CRT was associated with a worse outcome, especially in patients <60 years.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
In cases of simultaneous chemoradiotherapy (CRT), early recognition of toxic side effects is important, as drug discontinuation may prevent further injury. It appears favorable to undertake further steps to investigate whether patient subgroups behave differently depending on their toxicity profile.
METHODS METHODS
We retrospectively analyzed 125 consecutive patients with non-metastasized carcinoma of the head and neck who were treated with CRT (cisplatin 40 mg/m
RESULTS RESULTS
Eighty-six patients did not reach the intended sixth cycle (68.8%; 60.0% of whom were ≥60 years, p < 0.05). Acute kidney injury (glomerular filtration rate <60 mL/min/1.73m
CONCLUSION CONCLUSIONS
Acute kidney injury was the most common side effect in patients ≥60 years, whereas leukopenia characteristically occurred significantly more often in younger patients. Discontinuing cisplatin during CRT was associated with a worse outcome, especially in patients <60 years.

Identifiants

pubmed: 31784802
doi: 10.1007/s00066-019-01550-6
pii: 10.1007/s00066-019-01550-6
doi:

Substances chimiques

Antineoplastic Agents, Alkylating 0
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

515-521

Auteurs

Fabian Weykamp (F)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Katharina Seidensaal (K)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Stefan Rieken (S)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Kim Green (K)

Hospital Pharmacy, Heidelberg University Hospital, Heidelberg, Germany.

Stephan Mende (S)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Karim Zaoui (K)

Department of Otorhinolaryngology, Heidelberg University Hospital, Heidelberg, Germany.

Kolja Freier (K)

Department of Oral and Maxillofacial Surgery, Saarland University Medical Center, Homburg, Germany.

Sebastian Adeberg (S)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Jürgen Debus (J)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.

Stefan Ezechiel Welte (SE)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. Stefan.Welte@med.uni-heidelberg.de.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. Stefan.Welte@med.uni-heidelberg.de.
National Center for Tumor diseases (NCT), Heidelberg, Germany. Stefan.Welte@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH